Trial
NCT02985879
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
AbbVie
Collaborators
—
Condition
Progressive Supranuclear Palsy
Intervention
Placebo
Why stopped
This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy of study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-03